Pharmaceutical Composition for Alcohol Dependency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for alcohol dependence primarily focus on managing physical withdrawal symptoms rather than addressing the robust state of psychic dependence, leading to high relapse rates and limited efficacy due to significant side effects.
Innovation Solution
A pharmaceutical composition combining a compound with antagonistic action on 5-HT2 serotoninergic receptors, such as cyproheptadine, with a compound having antagonistic action on alpha1-noradrenergic receptors, like prazosin, alfuzosin, terazosin, or tamsulosin, to treat alcohol dependence, reducing the risk of major side effects while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naltrexone is used to treat alcohol dependence, then the desire to drink and relapse rate are reduced, but gastrointestinal side effects occur
Solution Approach 1:
The patent divides the treatment approach into two separate components: an opiate antagonist (for craving reduction) and a compound with antagonistic action on 5-HT2 serotoninergic receptors and/or alpha1-noradrenergic receptors (for side effect mitigation). This segmentation allows each component to address specific aspects of alcohol dependence treatment independently, reducing the burden of side effects while maintaining efficacy.
Solution Approach 2:
The invention combines two different pharmacological agents with distinct mechanisms of action into a single therapeutic regimen. The opiate antagonist targets the dopaminergic system to reduce craving, while the second compound acts on serotoninergic and/or noradrenergic systems to modulate mood and reduce side effects, creating a composite treatment that addresses multiple pathways involved in alcohol dependence.
2Object-affected harmful factors
If substitution products are used to limit physical withdrawal symptoms, then physical dependence symptoms are reduced, but psychic dependence remains unaddressed
Solution Approach 1:
The patent employs a multi-functional treatment approach where the combination of agents addresses both physical and psychic dimensions of alcohol dependence. The opiate antagonist primarily targets psychic dependence through dopaminergic modulation, while the second compound provides additional benefits for both physical symptom management and psychic dependence through its action on serotoninergic and noradrenergic systems, making the treatment universally applicable to multiple aspects of the disorder.
3Object-affected harmful factors
If acamprosate is used to modulate glutamatergic transmission, then withdrawal symptoms are treated, but efficacy against alcohol craving is uncertain
Solution Approach 1:
The patent changes the pharmacological parameters of the treatment by selecting agents with specific receptor profiles. Instead of relying solely on glutamatergic modulation, the invention uses an opiate antagonist combined with a compound targeting 5-HT2 serotoninergic and/or alpha1-noradrenergic receptors, thereby altering the mechanism of action to more directly address both craving and withdrawal symptoms with greater reliability.
Data Source
AI summary
Pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients:a compound having an antagonistic action on the 5-HT2 serotoninergic receptors selected as being cyproheptadine; anda compound having an antagonistic action on the alpha1-noradrenergic receptors selected from prazosin, alfuzosin, terazosin and tamsulosin.